WO2012019192A3 - Cell-permeable molecules as growth factor receptor antagonists - Google Patents
Cell-permeable molecules as growth factor receptor antagonists Download PDFInfo
- Publication number
- WO2012019192A3 WO2012019192A3 PCT/US2011/046956 US2011046956W WO2012019192A3 WO 2012019192 A3 WO2012019192 A3 WO 2012019192A3 US 2011046956 W US2011046956 W US 2011046956W WO 2012019192 A3 WO2012019192 A3 WO 2012019192A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- growth factor
- factor receptor
- cell
- molecules
- receptor antagonists
- Prior art date
Links
- 229940123011 Growth factor receptor antagonist Drugs 0.000 title 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000005202 lung cancer Diseases 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides growth factor receptor inhibitory molecules and methods of identifying such molecules, as well as methods of making such molecules and methods of using such molecules, for example in the treatment of cancer such as breast, colorectal, pancreatic, or lung cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37158910P | 2010-08-06 | 2010-08-06 | |
US61/371,589 | 2010-08-06 | ||
US201161454209P | 2011-03-18 | 2011-03-18 | |
US61/454,209 | 2011-03-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2012019192A2 WO2012019192A2 (en) | 2012-02-09 |
WO2012019192A3 true WO2012019192A3 (en) | 2012-05-03 |
Family
ID=45560114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2011/046956 WO2012019192A2 (en) | 2010-08-06 | 2011-08-08 | Cell-permeable molecules as growth factor receptor antagonists |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2012019192A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015515282A (en) | 2012-04-25 | 2015-05-28 | エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント | Compositions and methods for wound healing and tissue repair |
-
2011
- 2011-08-08 WO PCT/US2011/046956 patent/WO2012019192A2/en active Application Filing
Non-Patent Citations (6)
Title |
---|
A. BARDELLI ET AL: "Uncoupling signal transducers from oncogenic MET mutants abrogates cell transformation and inhibits invasive growth", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14379 - 14383, XP055012290, ISSN: 0027-8424, DOI: 10.1073/pnas.95.24.14379 * |
ANONYMOUS: "EGFR (Epidermal Growth Factor Receptor) inhibitor: Petide Antagonists targeting Juxtamembrane.", 23 July 2009 (2009-07-23), XP002663757, Retrieved from the Internet <URL:http://mssm.technologypublisher.com/technology/3228> [retrieved on 20111116] * |
CHRISTENSEN J G ET AL: "c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention", CANCER LETTERS, vol. 225, no. 1, 8 July 2005 (2005-07-08), NEW YORK, NY, US, pages 1 - 26, XP027608071, ISSN: 0304-3835, [retrieved on 20050708] * |
HOOSHMAND RAD ET AL: "PDGF alpha-receptor mediated cellular responses are not dependent on Src family kinases in endothelial cells.", JOURNAL OF CELL SCIENCE, vol. 111, no. 5, 1 March 1998 (1998-03-01), pages 607 - 614, XP055012379, ISSN: 0021-9533 * |
JAE-HO LEE ET AL: "A novel germ line juxtamembrane Met mutation in human gastric cancer", ONCOGENE, vol. 19, no. 43, 1 January 2000 (2000-01-01), pages 4947 - 4953, XP055012366, ISSN: 0950-9232, DOI: 10.1038/sj.onc.1203874 * |
P. M. CHAN ET AL: "Autoinhibition of the Kit Receptor Tyrosine Kinase by the Cytosolic Juxtamembrane Region", MOLECULAR AND CELLULAR BIOLOGY, vol. 23, no. 9, 1 May 2003 (2003-05-01), pages 3067 - 3078, XP055012332, ISSN: 0270-7306, DOI: 10.1128/MCB.23.9.3067-3078.2003 * |
Also Published As
Publication number | Publication date |
---|---|
WO2012019192A2 (en) | 2012-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2016204376A1 (en) | MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer | |
PH12013502230A1 (en) | Multispecific antibodies | |
WO2012088290A3 (en) | Tri-variable domain binding proteins and uses thereof | |
WO2012058592A3 (en) | Non-antagonistic egfr-binding molecules and immunoconjugates thereof | |
WO2011047087A3 (en) | Protein detection via nanoreporters | |
WO2010003520A3 (en) | Anti-tumor immunotherapy | |
MX2010004374A (en) | Protein scaffolds. | |
MX336001B (en) | Anti-axl antibodies and methods of use. | |
UA104459C2 (en) | Anti-fgfr3 antibodies and methods using same | |
WO2010099161A8 (en) | Micrornas in never-smokers and related materials and methods | |
WO2009108860A3 (en) | Microrna-based methods and compositions for the diagnosis, pronosis and treatment of prostate related disorders | |
MX2013004979A (en) | Dual variable domain immunoglobulins and uses thereof. | |
MX2013002270A (en) | Dual variable domain immunoglobulins and uses thereof. | |
TW201206473A (en) | Dual variable domain immunoglobulins and uses thereof | |
WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
MX2009008347A (en) | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use. | |
WO2014018563A3 (en) | Methods for the treatment of cancer | |
WO2009111643A3 (en) | Microrna markers for recurrence of colorectal cancer | |
WO2012016133A3 (en) | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers | |
WO2014018673A3 (en) | Fusion proteins and methods thereof | |
IN2009DN05670A (en) | ||
WO2011141823A3 (en) | Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists | |
EA201171367A1 (en) | VINYLINDASOLYL COMPOUNDS | |
PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
MX2013001473A (en) | Antibodies against il-18r1 and uses thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11750002 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11750002 Country of ref document: EP Kind code of ref document: A2 |